Standard treatment scheme
primary prostate cancer, prostate
SEMINAL VESICLES, LYMPH NODE METASTASES, PRIMARY PROSTATE CANCER, PROSTATE, LYMPH NODE METASTASIS, METASTASES
Included patients will receive standard of care EBRT and ADT with curative intent according to current clinical guidelines. EBRT involves 35 fractions intensity modulated radiotherapy (IMRT), 5 days per week over 7 weeks, delivering physical doses of 70–77 Gy to the prostate (and seminal vesicles if applicable), 60–63.35 Gy to macroscopic lymph node metastases, and 52.5–56.35 Gy to RTOG-based elective pelvic nodal fields expanded to include all detected nodal metastases (Fig. Example radiation field. Example of a radiation field in a patient with primary prostate cancer (indicated by a green arrow) and one lymph node metastasis in the left pelvic area (indicated by a red arrow) who is eligible for external beam radiation therapy (EBRT) and participation in the study. The delivered physical EBRT dose is 70–77 Gy to the prostate (purple area with green arrow), 60 Gy to macroscopic lymph node metastases (purple area with red arrow), and 52.5 Gy to the RTOG-based elective pelvic nodal fields expanded to include all detected nodal metastases (pink area)